<DOC>
	<DOCNO>NCT02440464</DOCNO>
	<brief_summary>This study design compare progression-free survival ( PFS ) randomization among patient randomize BMT CTN 1302 protocol , `` Multicenter Phase II , Double-blind Placebo Controlled Trial Maintenance Ixazomib Allogeneic Hematopoietic Stem Cell Transplantation High Risk Multiple Myeloma '' . It hypothesize Ixazomib maintenance therapy result improve PFS patient high-risk multiple myeloma follow Allogeneic Hematopoietic Stem Cell Transplantation ( HSCT ) compare placebo .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib High Risk Multiple Myeloma ( BMT CTN 1302 )</brief_title>
	<detailed_description>The study design Phase II , multi-center double-blind trial randomize patient high risk Multiple Myeloma Ixazomib maintenance placebo 60-120 day allogeneic HSCT . The primary objective randomize trial compare progression free survival randomization time event endpoint patient randomize Ixazomib maintenance placebo . Secondary objective describe treatment arm : rate grade II-IV III-IV Graft-Versus-Host-Disease ( GVHD ) , chronic GVHD , best disease response rate , disease progression , transplant related mortality , overall survival , rate Grade ≥ 3 toxicity accord Common Terminology Criteria Adverse Events ( CTCAE ) Version 4.0 , incidence infection , health-related quality life .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>1 . Age ≥ 18.0 year &lt; 66.0 year time enrollment . 2 . Patients must meet ONE criterion outline either , b , c OR : 1 . Patients high risk multiple myeloma partial response ( PR ) good time enrollment prior progression within 18 month initiation systemic antimyeloma therapy , may include single plan tandem autologous HSCT . [ High risk define presence one following : deletion chromosome 13 conventional cytogenetics , hypodiploidy , abnormality chromosome 1 ( 1q amplification 1p deletion ) , ( 4 ; 14 ) , ( 14 ; 16 ) , ( 14 ; 20 ) deletion 17p fluorescence situ hybridization ( FISH ) conventional karyotyping ; high risk criterion base commercially available gene expression profile ( GEP ) ; elevate beta2 microglobulin ( ≥ 5.5 mg/L diagnosis ) , detect time prior enrollment ] ; 2 . Patients high risk multiple myeloma ( criterion 3a ) good partial response ( VGPR ) good time enrollment 1 prior progression within 18 month initiation systemic antimyeloma therapy , may include single plan tandem autologous HSCT ; 3 . Patients standard risk multiple myeloma VGPR good time enrollment 1 prior progression within 18 month single plan tandem autologous HSCT ; 4 . Patients primary plasma cell leukemia VGPR good time enrollment prior disease progression within 18 month prior initiation antimyeloma therapy may include single plan tandem autologous transplant . 3 . Patients must relate unrelated peripheral blood stem cell donor meet one follow criterion : 1 . A sibling donor 6/6 match HLAA B ( intermediate high resolution ) DRB1 ( high resolution use DNAbased type ) must willing donate peripheral blood stem cell meet institutional criterion donation OR 2 . A related donor ( sibling ) 8/8 match HLAA , B , C ( intermediate high resolution ) DRB1 ( high resolution use DNAbased type ) must willing donate peripheral blood stem cell meet institutional criterion donation OR 3 . An unrelated donor 8/8 match HLAA , B , C , DRB1 ( high resolution use DNAbased type ) must willing donate peripheral blood stem cell meet institutional criterion donation . 4 . Cardiac function : Ejection fraction &gt; 40 % 5 . Estimated creatinine clearance great 40 mL/minute ( use CockcroftGault formula actual body weight ) 6 . Pulmonary function : Diffusing capacity lung carbon monoxide ( DLCO ) ≥ 40 % ( adjust hemoglobin ) force expiratory volume one second ( FEV1 ) ≥ 50 % 7 . Liver function : total bilirubin &lt; 2x upper limit normal alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) &lt; 2.5x upper normal limit ( Patients Gilbert 's Disease permit exceed define bilirubin value 2x upper limit normal , however measurement direct bilirubin do confirm diagnosis ) . 8 . Female subject ( unless postmenopausal least 1 year screen visit , surgically sterilize ) , agree practice two ( 2 ) effective method contraception time , agree practice true abstinence line prefer usual lifestyle subject ( Periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception ) 90 day last dose maintenance therapy ( see Section 2.6.2 definition postmenopausal ) . 9 . Male subject ( even surgically sterilize ) must agree one following : practice effective barrier contraception ( see Section 2.6.4.1 list barrier method ) , practice true abstinence line prefer usual lifestyle subject . Periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method time sign informed consent 90 day last dose maintenance therapy . 10 . Voluntary write consent must give performance study relate procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care . 11 . Able comply study visit schedule protocol requirement . 1 . Karnofsky Performance Score &lt; 70 % 2 . Prior allogeneic HSCT 3 . Patient purely nonsecretory multiple myeloma [ absence monoclonal protein ( M protein ) serum measure electrophoresis immunofixation absence Bence Jones protein urine define use conventional electrophoresis immunofixation technique absence involve serum free light chain &gt; 100 mg/L ] . 4 . Planned preemptive/prophylactic administration donor lymphocyte ( per section 2.5.2 ) 5 . Central Nervous System ( CNS ) involvement multiple myeloma define csf positivity plasma cell parenchymal CNS plasmacytoma 6 . Patients uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical improvement ) time enrollment . 7 . Presence fluid collection ( ascites , pleural , pericardial effusion ) interfere methotrexate clearance make methotrexate use contraindicate . 8 . Patients seropositive human immunodeficiency virus ( HIV ) . 9 . Patient active Hepatitis B C determine serology and/or NAAT . 10 . Patients hypersensitivity bortezomib , boron mannitol . 11 . Known GI disease GI procedure could interfere oral absorption tolerance MLN9708 include difficulty swallowing . 12 . Known allergy study medication , analogue , excipients various formulation agent . 13 . Patients &gt; grade 2 sensory peripheral neuropathy . 14 . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see Appendix D ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . 15 . Female patient lactate pregnant 16 . Prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent &gt; 5 year previously allow . Cancer treat curative intent &lt; 5 year , remission , review casebycase basis Protocol Officer one Protocol Chairs . 17 . Patients multiorgan involvement amyloidosis evidence amyloidosisrelated organ dysfunction 18 . Failure fully recover ( i.e . toxicity &gt; Grade 1 ) reversible effect prior chemotherapy . 19 . Patient serious medical psychiatric illness likely interfere participation clinical study 20 . Participation clinical trial investigational agent include trial , within 14 day start trial throughout duration trial . 21 . Patients receive radiation therapy within 3 week transplant . Enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy . 22 . Patients unable unwilling adhere study assessment schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Allogeneic Transplant</keyword>
	<keyword>Maintenance Therapy</keyword>
	<keyword>Anti-Myeloma Agents</keyword>
	<keyword>Hematologic Disorders</keyword>
</DOC>